Channel
@biomoment
On this record: Growth · Engagement · Reactions · Posts · Citations · Cite this entry
3,860subscribers
-2 since we began measuring on 7 August 2026
Risers and fallers across the register · movement among entries of 3,162–10,000.
| Telegram ID | -1001708733636 |
|---|---|
| Type | Channel |
| Username | @biomoment |
| Created | 8 September 2022 — measured — cross-checked against a third-party dataset (ext.tg_channel) |
| First recorded | 7 August 2026 |
| Last confirmed live | 11 August 2026 |
| Measurements held | 3 |
| Confirmed unchanged | 1 time, most recently 11 August 2026 |
| On Telegram | t.me/biomoment |
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 11 Aug 2026, 01:31 | 3,860 | +1 |
| 8 Aug 2026, 07:38 | 3,859 | -3 |
| 7 Aug 2026, 14:19 | 3,862 | first reading |
20 posts held, back to 31 August 2025 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 3 pagesof Telegram’s post history, 20 posts per page.
Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 20 posts for this entry, the most recent from 24 January 2026. An engagement rate over an empty window would be a number about nothing.
443 reactions across 17 posts, in 2 distinct kinds. The most used accounts for 84.7% of them.
| Reaction | Count | Share | Share, drawn |
|---|---|---|---|
| ❤ | 375 | 84.7% | |
| 👍 | 68 | 15.3% |
No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.
Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.
Coverage. Reactions were read on 17 of the 20 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 443reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.
Measured over the 20 most recent posts we hold, published 31 August 2025 to 24 January 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.
지인 위주로만 운영하던 Oncology 텔레그램을 다시 Public으로 전환하게 되었습니다. - 상장사/비상장사에 대한 긍정적/부정적 의견은 쓰지 않을 예정입니다(예상치 못한 부작용이 생기는 것 같습니다). - Oncology 전반적인 트렌드와 시황에 대한 내용은 업데이트 할 예정입니다. - 기존 텔레그램과 달리 Science 관련 내용만 전문적으로 다루게 될 것 같습니다. - 예전처럼 정리하여 요약하는 글은 많지 않을 것 같아 보기 힘드실수도 있을 것 같습니다. 양해 부탁드립니다. 감사합니다.
❤118
https://t.me/BioMomentOncology
❤14
안녕하세요. 제가 오늘부로 BioMoment-Oncology 채널을 더 이상 운영하지 않기로 결정했습니다. 특별한 이유는 없고, 원래 개인 공부가 주 목적이었으나 구독자분들이 점점 늘어나면서 그 의미가 퇴색되는 것 같아 중단하기로 결정했습니다. 이 텔레에 그 동안 공부하면서 모아두었던 자료들이 많아 Archive 형태로만 남겨둘 예정입니다. 항상 부족하지만 글 봐주셔서 감사드립니다. 감사합니다.
❤212
비관론자처럼 대비하고 낙관론자처럼 꿈꿔라 - same as ever -
👍18
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS4165
👍1
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS4164
👍1
https://www.fiercebiotech.com/biotech/amgens-stomach-cancer-candidate-takes-turn-attenuated-os-benefits-final-phase-3-analysis Amgen과 Zai Labs가 공동개발중인 FGFR2b 타깃 mAb 'Bemarituzumab'이 Gastric Cancer 환자들을 대상으로 한 1차 치료제 임상3상 최종 분석에서 이전 분석과 비교해 'Attenuated' OS Benefits을 보였다고 발표했음(Fortitude-101). 자세한 결과는 공개하지 않았지만, FGFR2 타깃 약물들의 경우 결국 Ocular Toxicity 등을 포함한 Tox 이슈가 꽤나 있고, mAb 단독으로는 한계가 좀 있는 것 같음. 새로운 모달리티를 기반으로 한 접근법이 필…
❤3
https://www.annalsofoncology.org/article/S0923-7534(25)00928-7/abstract LEAP-003; Melanoma; 1st Line Pembrolizumab + Lenvatinib vs Pembrolizumab No PFS & OS Benefits IO + TKI가 모든 Indication에서 Clinical Benefits을 보이는 것은 아님. 텔레그램 링크: https://t.me/biomoment 작성자: 박동영
❤3
https://www.fiercebiotech.com/biotech/gileads-kite-pharma-erodes-23b-shelf-cell-therapy-deal-shoreline-biosciences Gilead, Shoreline Biosciences와의 CAR-NK 공동개발 계약 종료 Gilead는 혈액암 타깃 CAR-NK를 넘어 CAR-Macrophage까지 공동개발 영역을 확장하려고 계획했었으나 결국 파트너쉽을 조기에 종료했음. 현재 Gilead가 가장 관심이 많은건 In Vivo CAR-T인 것으로 보임. 텔레그램 링크: https://t.me/biomoment 작성자: 박동영
❤2
https://www.fiercebiotech.com/biotech/zymeworks-drops-clinical-stage-t-cell-engager-after-assessing-benefit-risk-profile Zymeworks가 MSLN(Mesothelin)xCD3 T Cell Engager 'ZW171'의 임상 개발을 중단한다고 발표했음. 자세한 결과는 공개하지 않았지만, Mesothelin과 관련된 'On-target Off-tumor Toxicity'가 임상 개발 중단의 주요한 원인이라고 설명했음. 텔레그램 링크: https://t.me/biomoment 작성자: 박동영
👍2
개인적으로는 ORM-1023이 제일 궁금함... SCLC는 ICI, T Cell Engager 보다는 ADC, DAC이 더 적합한 모달리티이긴 함.
👍15
ORM-6151의 임상 1상을 진행 중인 BMS는 최근 환자를 세 배로 확대하며 개발에 속도를 내고 있다. BMS는 2023년 오름테라퓨틱과 1억8000만달러(약 2500억원) 규모 기술이전 계약을 체결했으며, 이 중 1억달러를 선급금으로 지급했다. 이 대표는 “남은 마일스톤은 1년치 운영할 수 있는 자금이 들어오는 구조이기 때문에 안정적인 운영 재원이 될 수 있을 것”이라며 “ORM-6151의 순조로운 진행은 DAC 플랫폼의 파트너십 확대에도 긍정적인 영향을 미칠 것”이라고 했다. ORM-1153에 적용한 항체는 11월 초 미국혈액학회(ASH)의 초록 공개 시기에 발표한다. 이 대표는 “어떤 항체를 결합해 DAC를 설계했는지는 글로벌 제약사들이 가장 궁금해하는 부분”이라며 “ASH 초록을 통해 ORM-1153의 항체가 베일을 벗을 것”이…
👍12
Showing the 12 most recent of 20 posts we hold for @biomoment. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Republishes
Channels on the register whose posts this channel has forwarded.
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
Names
Channels on the register whose handles appear in this channel's posts.
A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 11 August 2026 — this entry's latest reading, not the date you are reading this.
“BioMoment-Oncology” (@biomoment), 3,860 subscribers as measured 11 August 2026. Telegram Register, tgregister.com/channel/biomoment.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.